Evidence map›Paper›PMID 28114383›Full record

ArticlePloS one2017

Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.

J Benjamin St Clair, Thiago Detanico, Katja Aviszus, Greg A Kirchenbaum, Merry Christie, John F Carpenter, Lawrence J Wysocki

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

J Benjamin St ClairDepartment of Biomedical Research, National Jewish Health, Denver CO, United States of America.
Thiago DetanicoDepartment of Biomedical Research, National Jewish Health, Denver CO, United States of America.
Katja AviszusDepartment of Biomedical Research, National Jewish Health, Denver CO, United States of America.
Greg A KirchenbaumIntegrated Department of Immunology, National Jewish Health and University of Colorado School of Medicine, Denver, Colorado, United States of America.
Merry ChristieDepartment of Pharmaceutical Sciences, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, United States of America.
John F CarpenterDepartment of Pharmaceutical Sciences, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, United States of America.
Lawrence J WysockiDepartment of Biomedical Research, National Jewish Health, Denver CO, United States of America.ORCID http://orcid.org/0000-0003-1463-4162

Funding

Medical Scientist Training ProgramT32GM008497 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI WILSON, CARA C. · 1993 to 2022
$15.2M
IMMUNE RECOGNITION AND TOLERANCE OF ANTIBODY DIVERSITYR01AI033613 · NIAID · NATIONAL JEWISH HEALTH · PI WYSOCKI, LAWRENCE J · 1993 to 2009
$2.7M
A Universal Strategy for Inducing Tolerance to Therapeutic MabR21AI121980 · NIAID · NATIONAL JEWISH HEALTH · PI WYSOCKI, LAWRENCE J · 2016 to 2017
$436k
A Reporter for Mutant Autoreactive B CellsR03AI088408 · NIAID · NATIONAL JEWISH HEALTH · PI WYSOCKI, LAWRENCE J · 2010 to 2011
$155k
Autoantibody and BCR peptide-specific T cells in lupus nephritisF30DK091102 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI ST CLAIR, JAMES BEN · 2011 to 2014
$142k
NIAID NIH HHS R01 AI033613NIAID NIH HHS R03 AI088408NIAID NIH HHS R21 AI121980NIDDK NIH HHS F30 DK091102NIGMS NIH HHS T32 GM008497
6 · The paper itself

Abstract

A paradox in monoclonal antibody (mAb) therapy is that despite the well-documented tolerogenic properties of deaggregated IgG, most therapeutic IgG mAb induce anti-mAb responses. To analyze CD4 T cell reactions against IgG in various physical states, we developed an adoptive transfer model using CD4+ T cells specific for a Vκ region-derived peptide in the hapten-specific IgG mAb 36-71. We found that heat-aggregated or immune complexes (IC) of mAb 36-71 elicited anti-idiotypic (anti-Id) antibodies, while the deaggregated form was tolerogenic. All 3 forms of mAb 36-71 induced proliferation of cognate CD4+ T cells, but the aggregated and immune complex forms drove more division cycles and induced T follicular helper cells (TFH) development more effectively than did the deaggregated form. These responses occurred despite no adjuvant and no or only trace levels of endotoxin in the preparations. Physical analyses revealed large differences in micron- and nanometer-sized particles between the aggregated and IC forms. These differences may be functionally relevant, as CD4+ T cell proliferation to aggregated, but not IC mAb 36-71, was nearly ablated upon peritoneal injection of B cell-depleting antibody. Our results imply that, in addition to denatured aggregates, immune complexes formed in vivo between therapeutic mAb and their intended targets can be immunogenic.

Indexed as

Adoptive TransferAnimalsAntibodies, Anti-IdiotypicAntibodies, MonoclonalAntigen-Antibody ComplexCD4-Positive T-LymphocytesImmune ToleranceImmunoglobulin GImmunophenotypingMiceAntibodies, Anti-IdiotypicAntibodies, MonoclonalAntigen-Antibody ComplexImmunoglobulin G

Identifiers

PMID28114383
PMCPMC5256993

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.